Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein.

摘要: Erythropoietin (EPO) is a potential new treatment for acute stroke. However, EPO does not cross the blood-brain barrier (BBB). has been re-engineered as an IgG-EPO fusion protein, where fused to heavy chain of chimeric monoclonal antibody (MAb) against mouse transferrin receptor (TfR), which designated cTfRMAb-EPO protein. The able penetrate BBB following intravenous (IV) administration owing transport on TfR. In present study, neuroprotective properties alone and protein IV injection were investigated in permanent middle cerebral artery occlusion (MCAO) model adult mouse. Following MCAO, mice treated with low (1000 U/kg) high (10,000 doses recombinant EPO, or (0.05 mg/kg) (1.0 Hemispheric stroke volume neural deficit scores quantitated 24h after MCAO. There was no reduction either dose 1.0 mg/kg hemispheric reduced 81% 78%. These studies demonstrate degrees neuroprotection when neurotrophin enable across administration.